{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:14:30Z","timestamp":1777515270287,"version":"3.51.4"},"reference-count":42,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Standard dapsone and clofazimine-containing multidrug therapy (MDT) for leprosy is limited by drug tolerability, which poses treatment adherence barriers. Although ofloxacin-based regimens are promising alternatives, current efficacy and safety data are limited, particularly outside of endemic areas. We evaluated treatment outcomes in patients with leprosy receiving ofloxacin-containing MDT (OMDT) at our center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective chart review of patients treated for leprosy at our center over an 8-year period (2011-2019). Primary outcomes evaluated were clinical cure rate, occurrence of leprosy reactions, antibiotic-related adverse events, and treatment adherence. Analyses were descriptive; however, data were stratified by age, sex, spectrum of disease, region of origin, and treatment regimen, and odds ratios were reported to assess associations with adverse outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over the enrolment period, 26 patients were treated with OMDT ( n = 19 multibacillary, n = 7 paucibacillary), and none were treated with clofazimine-based standard MDT. At the time of analysis, 23 patients (88%) had completed their course of treatment, and all were clinically cured, while 3 (12%) were still on treatment. Eighteen patients (69%) experienced either ENL ( n = 7, 27%), type 1 reactions ( n = 7, 27%), or both ( n = 4, 15%). No patients stopped ofloxacin due to adverse drug effects, and there were no cases of allergic hypersensitivity, tendinopathy or rupture, or C. difficile colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrate a high cure rate and tolerability of OMDT in this small case series over an 8-year period, suggesting its viability as an alternative to standard clofazimine-containing MDT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1203475420952437","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T07:03:42Z","timestamp":1598943822000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Ofloxacin-Containing Multidrug Therapy in Ambulatory Leprosy Patients: A Case Series"],"prefix":"10.1177","volume":"25","author":[{"given":"Lena","family":"Faust","sequence":"first","affiliation":[{"name":"McGill International TB Centre, Montreal, QC, Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Klowak","sequence":"additional","affiliation":[{"name":"Institute of Medical Science, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"MacRae","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swana","family":"Kopalakrishnan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Queen\u2019s University, Kingston, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne J.","family":"Showler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Toronto, Toronto, ON, Canada"},{"name":"Division of Infectious Diseases, Georgetown University, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-6944","authenticated-orcid":false,"given":"Andrea K.","family":"Boggild","sequence":"additional","affiliation":[{"name":"Tropical Disease Unit, Toronto General Hospital, Toronto, ON, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"1","key":"bibr1-1203475420952437","first-page":"55","volume":"170","author":"Boggild AK.","year":"2004","journal-title":"CMAJ"},{"key":"bibr2-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-017-0051-3"},{"key":"bibr3-1203475420952437","first-page":"389","volume":"94","author":"World Health Organization (WHO)","year":"2019","journal-title":"Wkly Epidemiol Rec"},{"issue":"34","key":"bibr4-1203475420952437","first-page":"317","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"bibr5-1203475420952437","first-page":"71","volume":"170","author":"Boggild AK.","year":"2004","journal-title":"CMAJ"},{"key":"bibr6-1203475420952437","volume-title":"Global Leprosy Strategy 2016\u20132020. Accelerating Towards a Leprosy-Free World","author":"World Health Organization (WHO)","year":"2017"},{"issue":"2","key":"bibr7-1203475420952437","doi-asserted-by":"crossref","first-page":"5.","DOI":"10.5070\/D31TD1J7FT","volume":"9","author":"Ishii N","year":"2003","journal-title":"Dermatol Online J"},{"key":"bibr8-1203475420952437","volume-title":"Guidelines for the Diagnosis, Treatment and Prevention of Leprosy","author":"World Health Organization (WHO)","year":"2018"},{"key":"bibr9-1203475420952437","unstructured":"World Health Organization.\n                      WHO Expert Committee on Leprosy, 7th Report\n                      . WHO Technical Report Series 874. 1998. Geneva; Switzerland. Accessed April 7, 2020. http:\/\/apps.who.int\/iris\/bitstream\/10665\/42060\/1\/WHO_TRS_874.pdf"},{"key":"bibr10-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2004.70.197"},{"issue":"2","key":"bibr11-1203475420952437","first-page":"149","volume":"80","author":"Rao PSS","year":"2008","journal-title":"Indian J Lepr"},{"key":"bibr12-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.57410"},{"key":"bibr13-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962013000200003"},{"key":"bibr14-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007671"},{"key":"bibr15-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr444"},{"key":"bibr16-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw004"},{"key":"bibr17-1203475420952437","unstructured":"World Health Organization.\n                      Chemotherapy of Leprosy\n                      . WHO Technical Report Series 847. 1994. Geneva: Switzerland."},{"key":"bibr18-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0953"},{"issue":"2","key":"bibr19-1203475420952437","first-page":"105","volume":"77","author":"Ali MKS.","year":"2005","journal-title":"Indian J Lepr"},{"key":"bibr20-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2009.09-0189"},{"key":"bibr21-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4100-6"},{"key":"bibr22-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.105274"},{"key":"bibr23-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.03.005"},{"key":"bibr24-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.662"},{"key":"bibr25-1203475420952437","doi-asserted-by":"publisher","DOI":"10.47276\/lr.81.3.228"},{"issue":"2","key":"bibr26-1203475420952437","first-page":"121","volume":"69","author":"Babu GR for the Single Lesion Multicentre Trial Group","year":"1997","journal-title":"Indian J Lepr"},{"key":"bibr27-1203475420952437","doi-asserted-by":"publisher","DOI":"10.5025\/hansen.76.207"},{"key":"bibr28-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2011.02873.x"},{"key":"bibr29-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k678"},{"key":"bibr30-1203475420952437","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2018. Accessed July 23, 2020. https:\/\/www.ema.europa.eu\/en\/news\/disabling-potentially-permanent-side-effects-lead-suspension-restrictions-quinolone-fluoroquinolone#:~:text=The%20serious%20side%20effects%20include,%2C%20vision%2C%20taste%20and%20smell"},{"key":"bibr31-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-018-0061-9"},{"key":"bibr32-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.108029"},{"key":"bibr33-1203475420952437","doi-asserted-by":"publisher","DOI":"10.47276\/lr.82.1.46"},{"key":"bibr34-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.159929"},{"key":"bibr35-1203475420952437","doi-asserted-by":"publisher","DOI":"10.47276\/lr.81.1.27"},{"issue":"3","key":"bibr36-1203475420952437","first-page":"283","volume":"68","author":"Majumder V.","year":"2000","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"bibr37-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2007.77.829"},{"key":"bibr38-1203475420952437","doi-asserted-by":"publisher","DOI":"10.1086\/378410"},{"key":"bibr39-1203475420952437","doi-asserted-by":"publisher","DOI":"10.47276\/lr.84.1.65"},{"key":"bibr40-1203475420952437","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0586"},{"key":"bibr41-1203475420952437","first-page":"176","volume":"4","author":"Sharma D.","year":"2017","journal-title":"Int J Indian Psychol"},{"issue":"2","key":"bibr42-1203475420952437","first-page":"1","volume":"2015","author":"Kumar A.","year":"2015","journal-title":"Biomed Res Int"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420952437","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1203475420952437","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1203475420952437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:54:41Z","timestamp":1777391681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1203475420952437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1203475420952437"],"URL":"https:\/\/doi.org\/10.1177\/1203475420952437","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}